Table 1.
Association between LGR5 and clinicopathological characteristics in high-grade serous carcinomas.
| Characteristics | No. of cases (%) | Epithelial LGR5 | P-value# | Stromal LGR5 | P-value# | ||
|---|---|---|---|---|---|---|---|
| Low (%) | High (%) | Low (%) | High (%) | ||||
| 64 (100) | 34 (53) | 30 (47) | 43 (67) | 21 (33) | |||
| Age (yr.) | |||||||
| < 55 | 33 (52) | 24 (73) | 9 (27) | 0.001 | 18 (55) | 15 (45) | 0.026 |
| ≥ 55 | 31 (48) | 10 (32) | 21 (67) | 25 (81) | 6 (19) | ||
| Family history of breast cancer | |||||||
| Absent | 61 (95) | 32 (52) | 29 (48) | 0.63 | 43 (71) | 18 (29) | 0.011 |
| Present | 3 (5) | 2 (67) | 1 (33) | 0 (0) | 3 (100) | ||
| Family history of ovarian cancer | |||||||
| Absent | 61 (95) | 32 (52) | 29 (48) | 0.63 | 41 (67) | 20 (33) | 0.984 |
| Present | 3 (5) | 2 (67) | 1 (33) | 2 (67) | 1 (33) | ||
| Menopause | |||||||
| No | 25 (39) | 16 (64) | 9 (36) | 0.163 | 14 (56) | 11 (44) | 0.127 |
| Yes | 39 (61) | 18 (46) | 29 (54) | 29 (74) | 10 (26) | ||
| Serum CA-125, IU/ml | |||||||
| < 700 | 34 (53) | 14 (41) | 20 (59) | 0.041 | 24 (71) | 10 (29) | 0.537 |
| ≥ 700 | 30 (47) | 20 (67) | 10 (33) | 19 (63) | 11 (37) | ||
| FIGO stage | |||||||
| 1–2 | 5 (8) | 3 (60) | 2 (40) | 0.918 | 2 (40) | 3 (60) | 0.269 |
| 3 | 41 (64) | 22 (54) | 19 (46) | 27 (66) | 14 (34) | ||
| 4 | 18 (28) | 9 (50) | 9 (50) | 14 (78) | 4 (22) | ||
| Malignant ascites | |||||||
| No | 7 (11) | 4 (57) | 3 (43) | 0.308 | 4 (57) | 3 (3) | 0.712 |
| Yes | 55 (86) | 30 (55) | 25 (45) | 38 (69) | 17 (31) | ||
| Unknown | 2 (3) | 0 (0) | 2 (100) | 1 (50) | 1 (50) | ||
| Residual tumor after operation | |||||||
| Absent | 43 (67) | 23 (54) | 20 (47) | 0.934 | 24 (56) | 19 (44) | 0.006 |
| Present | 21 (33) | 11 (52) | 10 (48) | 19 (91) | 2 (9) | ||
| Recurrence | |||||||
| No | 30 (47) | 11 (37) | 19 (63) | 0.013 | 18 (60) | 12 (40) | 0.250 |
| Yes | 34 (53) | 23 (68) | 11 (32) | 25 (74) | 9 (26) | ||
| Platinum sensitivity | |||||||
| Sensitive | 53 (83) | 30 (57) | 23 (43) | 0.247 | 38 (72) | 15 (28) | 0.331 |
| Resistant | 9 (14) | 4 (44) | 5 (56) | 5 (56) | 4 (44) | ||
| Not applicable | 2 (3) | 0 (0) | 2 (100) | 0 (0) | 2 (100) | ||
| Germline BRCA1 mutation | |||||||
| Absent | 44 (69) | 24 (55) | 20 (45) | 0.736 | 29 (66) | 15 (34) | 0.747 |
| Present | 20 (31) | 10 (50) | 10 (50) | 14 (70) | 6 (30) | ||
| Germline BRCA2 mutation | |||||||
| Absent | 57 (89) | 31 (54) | 26 (46) | 0.564 | 38 (67) | 19 (33) | 0.800 |
| Present | 7 (11) | 3 (43) | 4 (57) | 5 (71) | 2 (29) | ||
| Germline BRCA1 or 2 mutations | |||||||
| Absent | 38 (59) | 21 (55) | 17 (45) | 0.679 | 25 (66) | 13 (34) | 0.773 |
| Present | 26 (41) | 13 (50) | 13 (50) | 18 (69) | 8 (31) | ||
| Estrogen receptor | |||||||
| Negative | 24 (37) | 12 (50) | 12 (50) | 0.698 | 26 (65) | 14 (35) | 0.630 |
| Positive | 40 (63) | 22 (55) | 18 (45) | 17 (71) | 7 (29) | ||
No. Number; FIGO International Federation of Gynecology and Obstetrics.
#Pearson chi-square test.